Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β-Amyloid Toxicity and Are Mediated by Tau

Neurotherapeutics

Volumn 12, Issue 4, 2015, Pages 862-873

  Li, Xuling ^a,b   Lei, Peng ^b   Tuo, Qingzhang ^b,c   Ayton, Scott ^b   Li, Qiao Xin ^b   Moon, Steve ^b   Volitakis, Irene ^b   Liu, Rong ^c   Masters, Colin L ^b   Finkelstein, David I ^b   Bush, Ashley I ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Aging; Alzheimer s disease; Iron; Neuroprotection; Tau; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; IRON; OLIGOMER; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); ENOLASE; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; MOUSE; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; Y-MAZE TEST; AGE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENETICS; IN VITRO STUDY; MAZE TEST; METABOLISM; RECOGNITION; TIME FACTOR;

AGE FACTORS; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; IN VITRO TECHNIQUES; IRON; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PHOSPHOPYRUVATE HYDRATASE; RECOGNITION (PSYCHOLOGY); TAU PROTEINS; TIME FACTORS;

EID: 84973925444     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0378-2     Document Type: Article

References (47)

1. Liu T, Perry G, Chan HW, et al. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 2004;88:554–563.
2. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 2002;99:6364–6369.
3. Vossel KA, Zhang K, Brodbeck J, et al. Tau reduction prevents A{beta}-induced defects in axonal transport. Science 2010;330:198.
4. Shipton OA, Leitz JR, Dworzak J, et al. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci 2011;31:1688–1692.
5. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 2007;316:750–754.
6. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 2010;142:387–397.
7. Leroy K, Ando K, Laporte V, et al. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am J Pathol 2012;181:1928–1940.
8. Ahmed T, Van der Jeugd A, Blum D, et al. Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion. Neurobiol Aging 2014;35:2474–2478.
9. Kimura T, Whitcomb DJ, Jo J, et al. Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Philos Trans R Soc Lond B Biol Sci 2014;369:20130144.
10. Regan P, Piers T, Yi JH, et al. Tau phosphorylation at serine 396 residue is required for hippocampal LTD. J Neurosci 2015;35:4804–4812.
11. Lei P, Ayton S, Finkelstein DI, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012;18:291–295.
12. Ma QL, Zuo X, Yang F, et al. Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging. J Neurosci 2014;34:7124–7136.
13. Lei P, Ayton S, Moon S, et al. Motor and cognitive deficits in aged tau knockout mice in two background strains. Mol Neurodegener 2014;9:29.
14. Lei P, Ayton S, Appukuttan AT, et al. Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiol Dis 2015 Mar 18 [Epub ahead of print].
15. Dawson HN, Cantillana V, Jansen M, et al. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer’s disease. Neuroscience 2010;169:516–531.
16. Smith MA, Siedlak SL, Richey PL, et al. Tau protein directly interacts with the amyloid beta-protein precursor: implications for Alzheimer’s disease. Nat Med 1995;1:365–369.
17. Duce JA, Tsatsanis A, Cater MA, et al. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell 2010;142:857–867.
18. Baleriola J, Walker CA, Jean YY, et al. Axonally synthesized ATF4 transmits a neurodegenerative signal across brain regions. Cell 2014;158:1159–1172.
19. Dawson HN, Ferreira A, Eyster MV, et al. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 2001;114:1179–1187.
20. Li QX, Mok SS, Laughton KM, et al. Overexpression of Abeta is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. Aging Cell 2006;5:153–165.
21. Sotthibundhu A, Sykes AM, Fox B, et al. Beta-amyloid(1–42) induces neuronal death through the p75 neurotrophin receptor. J Neurosci 2008;28:3941–3946.
22. Desbene C, Malaplate-Armand C, Youssef I, et al. Critical role of cPLA2 in Abeta oligomer-induced neurodegeneration and memory deficit. Neurobiol Aging 2012;33:1123 e1117-e1129.
23. Amini E, Nassireslami E, Payandemehr B, et al. Paradoxical role of PKA inhibitor on amyloidbeta-induced memory deficit. Physiol Behav 2015;149:76–85.
24. Moon M, Choi JG, Nam DW, et al. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-beta1-42 oligomer-injected mice. J Alzheimers Dis 2011;23:147–159.
25. Gittins R, Harrison PJ. Neuronal density, size and shape in the human anterior cingulate cortex: a comparison of Nissl and NeuN staining. Brain Res Bull 2004;63:155–160.
26. Stohr J, Watts JC, Mensinger ZL, et al. Purified and synthetic Alzheimer’s amyloid beta (Abeta) prions. Proc Natl Acad Sci U S A 2012;109:11025–11030.
27. Li QX, Maynard C, Cappai R, et al. Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer’s disease precursor protein in the hippocampus of aged transgenic mice. J Neurochem 1999;72:2479–2487.
28. Ayton S, Lei P, Bush AI. Biometals and their therapeutic implications in Alzheimer’s disease. Neurotherapeutics 2015;12:109–120.
29. Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem 2002;277:45518–45528.
30. Ayton S, Lei P, Hare DJ, et al. Parkinson’s disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. J Neurosci 2015;35:3591–3597.
31. Maynard CJ, Cappai R, Volitakis I, et al. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. J Inorg Biochem 2006;100:952–962.
32. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001;293:1491–1495.
33. Forny-Germano L, Lyra ESNM, Batista AF, et al. Alzheimer’s disease-like pathology induced by amyloid-beta oligomers in nonhuman primates. J Neurosci 2014;34:13629–13643.
34. Rosen RF, Fritz JJ, Dooyema J, et al. Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. J Neurochem 2012;120:660–666.
35. Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994;265:1464–1467.
36. Jankowsky JL, Younkin LH, Gonzales V, et al. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem 2007;282:22707–22720.
37. Levi O, Dolev I, Belinson H, Michaelson DM. Intraneuronal amyloid-beta plays a role in mediating the synergistic pathological effects of apoE4 and environmental stimulation. J Neurochem 2007;103:1031–1040.
38. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2013;12:357–367.
39. Hare D, Ayton S, Bush A, Lei P. A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci 2013;5:34.
40. de Lima MN, Dias CP, Torres JP, et al. Reversion of age-related recognition memory impairment by iron chelation in rats. Neurobiol Aging 2008;29:1052–1059.
41. Becerril-Ortega J, Bordji K, Freret T, Rush T, Buisson A. Iron overload accelerates neuronal amyloid-beta production and cognitive impairment in transgenic mice model of Alzheimer’s disease. Neurobiol Aging 2014;35:2288–2301.
42. Guo C, Wang T, Zheng W, et al. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer’s disease. Neurobiol Aging 2013;34:562–575.
43. Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 1991;337:1304–1308.
44. Ayton S, Faux NG, Bush AI. Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE. Nat Commun 2015;6:6760.
45. Wong BX, Tsatsanis A, Lim LQ, et al. beta-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS ONE 2014;9:e114174.
46. McCarthy RC, Park YH, Kosman DJ. sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep 2014;15:809–815.
47. Braak H, Del Tredici K. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 2011;121:171–181.